Oura sells a ring that costs a few hundred dollars. Until this week, investors were preparing to value the company behind it at as much as $15.6 billion, a figure that says considerably more about the future of health technology than it does about jewellery.

The Finnish-founded company had been preparing one of the most closely watched consumer technology listings of the year, offering 50 million shares at between $40 and $44 each. On Tuesday, Oura postponed the IPO, citing uncertainty in the market despite what it described as strong demand, delaying a listing that could have raised as much as $2.2 billion.

The delay matters to investors, but it does little to change the more interesting story underneath Oura’s prospectus. A company once associated with sleep scores and Silicon Valley biohackers is rapidly accumulating something potentially much more valuable: a continuous stream of health information generated by millions of people, every hour of every day.

Five million people are already wearing one

Oura’s growth has been extraordinary. Revenue reached $1.21 billion during the nine months to June 2026, up 74 per cent from the same period a year earlier, while net income climbed to $60.8 million from just $1.6 million.

The company had five million paying members by the end of June and expects that figure to reach around 5.7 million for the full financial year. Oura sold 3.6 million rings during the 12 months to June alone, while its 12-month membership retention rate has been approximately 85 per cent.

Those numbers begin to explain why investors have been willing to entertain such a large valuation. Oura is selling hardware, but every ring also establishes an ongoing relationship with a customer whose sleep, activity, stress, temperature and cardiovascular signals can be measured repeatedly over months or years.

Subscriptions make that relationship considerably more attractive. Membership revenue more than doubled to around $240 million in the first nine months of the financial year, although hardware still accounted for roughly 80 per cent of total revenue.

The result is a business that sits somewhere between consumer electronics and digital health. Which side of that line investors eventually decide Oura belongs on could determine how valuable the company ultimately becomes.

The ring is becoming the least interesting part

Wearables have traditionally been sold around a relatively simple proposition: collect information about yourself and use it to become fitter or healthier. Oura’s ambition is moving considerably further into health, with its platform already producing more than 50 metrics and increasingly using AI to turn continuous sensor readings into personalised guidance.

That changes the economics of the product. A ring can be sold once, while a health platform can maintain a relationship with a user for years, generating subscription revenue and building increasingly deep longitudinal datasets as it does so.

The healthcare implications are more significant still. Most conventional healthcare data is episodic, generated when somebody visits a GP, enters hospital, undergoes a test or receives treatment, while consumer wearables can observe changes between those encounters.

A device worn day and night can potentially identify patterns in sleep, temperature, cardiovascular activity and recovery long before those signals would ordinarily appear in a medical record. Turning that information into clinically meaningful evidence remains a much harder task, but the attraction for healthcare systems, researchers and pharmaceutical companies is obvious.

One detail in Oura’s planned IPO underlines that direction. Eli Lilly, one of the world’s largest pharmaceutical companies, had indicated interest in buying up to $100 million of shares in the offering, while Oura already reaches users through healthcare partners, employers and government organisations as well as direct consumer sales.

Health data changes the stakes

Oura’s evolution also creates a more difficult question about where wellness ends and healthcare begins. A consumer may buy a ring to improve their sleep, but the same device can generate information about heart rate, body temperature, stress and other physiological changes that increasingly resembles the kind of longitudinal monitoring healthcare providers have spent years trying to achieve.

That does not make Oura a medical device across all of its functions, and the distinction matters. The company itself has stressed that its ring is not a substitute for a clinical sleep study, even as it argues that its sleep-staging technology has performed favourably against polysomnography in multiple studies.

The issue is already being tested. Oura is facing a proposed class-action lawsuit challenging claims about the accuracy of its sleep tracking, allegations the company disputes and says it will defend against.

Accuracy becomes considerably more consequential as wearables move towards healthcare decision-making. Consumers tolerating an imperfect readiness score is one thing, while clinicians, researchers or health systems relying on continuously generated biometric information demands a much higher standard of evidence.

Apple is watching the same opportunity

Oura is unlikely to have this territory to itself. Apple, Google, Samsung and specialist wearable companies are competing for variations of the same prize: becoming the device that people are prepared to wear continuously enough to create a useful picture of their health.

That competition explains why Oura’s position is both powerful and vulnerable. Its screen-free ring has established a distinctive category and considerable consumer loyalty, but much larger technology companies already control smartphones, watches, operating systems and health platforms used by hundreds of millions of people.

Oura therefore has to prove that its advantage extends beyond the form factor wrapped around somebody’s finger. Its increasingly large dataset, subscription relationship and ability to translate continuous measurements into useful health information may ultimately provide a stronger defence than the ring itself.

The IPO can wait. The bigger experiment cannot.

Financial markets have temporarily interrupted Oura’s public-market debut. Rising bond yields, changing expectations around US interest rates and wider market volatility have made investors more cautious, prompting Oura to postpone a listing that had reportedly attracted substantial demand.

The underlying numbers have not disappeared with the IPO. Oura is profitable, growing quickly and approaching six million paying members, giving it an unusually large population generating continuous health information outside traditional healthcare settings.

That makes Oura part of a much larger shift already taking place across healthcare. The medical record has historically been a record of what happens when a patient encounters the health system, while wearables are beginning to create a record of what happens during the thousands of hours when they do not.

Oura may eventually return to the Nasdaq when markets settle. By then, the more consequential question may be whether investors still see a company selling smart rings, or one quietly building an entirely different kind of health infrastructure.

‍